Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cystic fibrosis (CF). It develops nucleotide-binding domain 1 (NBD1) stabilizers that normalize CFTR function for CF patients; Galicaftor (SION-2222) and SION-2851; SION-109, an ICL4-directed CFTR corrector; and Navocaftor (SION-3067), a potentiator. Sionna Therapeutics, Inc. formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. The company was incorporated in 2019 and is based in Waltham, Massachusetts.